Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs, Inc. develops clinical-stage biopharmaceutical candidates for cardiometabolic diseases by targeting the biology of human aging. Its news centers on BGE-102, a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, including diabetic macular edema.
Recurring updates cover Phase 1 biomarker and tolerability data, indication development for inflammation-driven disease, and research into long-acting injectable and oral small-molecule APJ agonists for obesity. BioAge also reports financial results, public offerings, R&D presentations, and collaborations that use its human longevity data platform to identify metabolic-aging pathways.
BioArctic (Nasdaq Stockholm: BIOA B) reported that partner Eisai presented interim real-world data from the three-year LEADER study of Leqembi in early Alzheimer's disease at AAIC 2026. Among 427 evaluable patients treated for an average of 17 months (mean 520 days, 26 doses), 82.5% remained stable or improved in disease stage, with 75.9% stable and 6.6% improving from mild AD dementia to MCI due to AD. Results were consistent across sex, race, ethnicity and APOE genotype, and nearly 87% of patients chose to remain on treatment.
In 155 patients on once-every-four-weeks IV maintenance, about 81% were stable or improved, while 12 of 14 on weekly SC maintenance maintained stage. Overall safety was described as consistent with the US FDA-approved label; ARIA occurred in 12.3% of patients, mostly asymptomatic and mild, with no new ARIA-E events, macrohemorrhages or intracerebral hemorrhages >1 cm during IV maintenance.
BioArctic (Nasdaq Stockholm: BIOA B) reports that partner Eisai has received FDA approval for a supplemental Biologics License Application for once-weekly subcutaneous Leqembi Iqlik (lecanemab-irmb) as a starting dose for treating early Alzheimer's disease in US adults. The US launch is planned for late August 2026.
The approved initiation regimen is 500 mg once weekly, delivered as two 250 mg autoinjector doses of about 15 seconds each. Leqembi Iqlik is already approved in the US for maintenance at 360 mg once weekly after 18 months of IV or SC treatment, enabling at-home therapy from initiation through maintenance with flexibility to switch between IV and SC administration.
According to BioArctic, sub-studies from the Phase 3 Clarity AD long-term extension showed subcutaneous dosing achieved exposure equivalent to IV, supporting similar efficacy and amyloid removal, with a generally similar safety profile. Injection-related reactions were observed, mostly localized, and systemic reactions were less frequent. An autoinjector acceptability study found 94% of patients and care partners considered the device easy to use with high satisfaction in at-home settings.
BioArctic (Nasdaq Stockholm: B) announced that its partner Eisai presented new data at AAIC 2026 in London showing the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) achieved pharmacokinetic exposure comparable to the approved IV initiation regimen in early Alzheimer's disease.
Once-weekly 500 mg SC-AI was bioequivalent to IV 10 mg/kg every two weeks, with an exposure ratio of 104% (90% CI: 99.1%–109%), and consistent results across body-weight groups, supporting a fixed-dose regimen. Clinical and biomarker outcomes, including amyloid PET, CDR-SB and ARIA-E incidence, were described as driven by lecanemab exposure rather than administration route.
The SC-AI formulation showed a safety profile generally aligned with IV Leqembi, with mostly localized injection reactions, low anti-drug antibody incidence of 1.4% and no neutralizing antibodies. Early clinical practice data from two US centers indicated slower cognitive decline or stable cognition in treated patients, plus high patient and care partner satisfaction, convenience and willingness to recommend treatment.
BioArctic (NASDAQ Stockholm: BIOA B) announced that partner Eisai will present extensive new clinical and real-world evidence on lecanemab (Leqembi) at the AAIC 2026 conference in London, July 12–15. Highlights include subcutaneous dosing, long-term and maintenance use, at-home administration, and multiple real-world and preclinical Alzheimer’s studies.
BioArctic (NASDAQ STOCKHOLM:B) announced a research and collaboration agreement with Eli Lilly to combine BioArctic's BrainTransporter technology with an undisclosed Lilly neurodegeneration drug candidate. BioArctic receives USD 30 million upfront, is eligible for up to USD 770 million in milestones, plus tiered mid-single digit royalties.
Lilly will handle global development and commercialization. This is BioArctic's fourth BrainTransporter collaboration, while it retains platform rights outside the four deals. The project uses an investigational agent, with no assurance of clinical success or regulatory approval.
BioAge Labs (Nasdaq:BIOA) has dosed the first participant in QUELL-CV, a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept trial of oral NLRP3 inhibitor BGE-102 in adults at elevated cardiovascular risk.
The 12-week trial will enroll ~160 participants across four arms to evaluate three once-daily doses versus placebo, with percent change in high-sensitivity C-reactive protein (hsCRP) as the primary endpoint and topline data expected in the second half of 2026.
BioArctic (Nasdaq Stockholm: BIOA B) issued 5,000 Class B shares in May 2026 through exercise of 5,000 stock options from the 2019/2028 program. As of May 29, 2026, BioArctic has 88,724,485 shares outstanding and 218,324,449 votes in total.
The share capital comprises 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. Each A share carries ten votes and each B share one vote.
BioArctic (Nasdaq Stockholm: BIOA B) held its AGM on 28 May 2026 and approved the 2025 income statement and balance sheet, a dividend of SEK 2 per share with record date 1 June 2026, and discharge of the board and CEO.
Shareholders re-elected six directors, elected two new members, and re-elected the chair. The AGM authorised the board to issue new shares, warrants and convertibles of up to 10% of share capital, adopted a three-year PSU incentive program of up to 235,000 units with related hedging, and updated senior executive remuneration guidelines.
BioArctic (NASDAQ Stockholm: B) reported that partner Eisai presented a simulation of potential future Leqembi sales at its Investor Relations Day.
According to Eisai, simulated Leqembi sales reach around JPY 300 billion (≈SEK 17.6 billion) in FY2028, ending March 2029. The disclosure was made under EU Market Abuse Regulation rules.
BioAge Labs (NASDAQ:BIOA) will participate in two upcoming investor conferences. Management will join fireside chats and one-on-one meetings at the Jefferies Global Healthcare Conference in New York on June 4, 2026, and the Goldman Sachs Global Healthcare Conference in Miami Beach on June 8, 2025.
Live webcasts will be accessible via registration links, with replays available for 30 days in the investor section of BioAge’s website.